World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London
The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/
Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire)
The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based processes that show results in patient safety – and for developing new APSS. These sessions provide healthcare professionals, advocates, and enthusiasts the opportunity to contribute their experiences and expertise, which is critical to process improvement, while also promoting transparency and encouraging aligned incentives that will eventually lead to ZERO preventable patient deaths in hospitals by 2020.
The World Patient Safety, Science & Technology Summit, and Breakout Sessions are supported by the Rt. Hon Jeremy Hunt, MP, Secretary of State for Health and Social Care, Department of Health United Kingdom and co-convened by the European Society of Anaesthesiology. This year’s breakout sessions will include:
Many healthcare institutions can improve patient safety through procedures related to immunization, safety monitoring, and pertinent participatory information systems. This session will exchange the latest advances in patient and vaccine safety research methods, and pertinent key performance indicators for healthcare institutions. Finally, the group will crystallize the plans for developing an Actionable Patient Safety Solutions (APSS) that focuses on safeguarding patients through engagement, protecting the providers caring for patients, and shielding at-risk patients. Other key topics of discussion will include systematic monitoring of adverse events and feedback knowledge updates for healthcare providers.
Person and Family Engagement (PFE)
Person and Family Engagement is an underused “natural resource” for improving patient safety. Ample evidence has accumulated which demonstrates that when patients are actively engaged partners, they achieve better outcomes and help produce innovative solutions. Persons who use care or manage its use for loved ones are highly motivated to partner with professional and organizational care providers to drive change across the care continuum. Their experiences bring an urgency to the patient safety movement that propels action by generating empathy – they engage our hearts as well as our minds and hands.
Injuries related to falls impose a catastrophic cost of care on families and healthcare economics. Fall prevention and injury reduction require a collaborative approach involving leadership, clinical intervention, and patent and family partnership. This session will explore the Actionable Patient Safety Solutions for Fall Prevention and Injury Reduction. The latest research and science will be discussed along with revisions to the APSS that can assist in care that reduces harm, injury, and death.
Driving Sustainable Change in Hand Hygiene - The Problem We Only THINK We Solved
If hand hygiene is the most effective way to prevent avoidable HAIs, why is global compliance below 50%? Recent studies prove that three elements are essential for sustainable improvement: Accurate measurement, evidence-based feedback, and top-down accountability. The current hand hygiene APSS incorporates this learning into actionable guidelines. Attendees will learn how to translate emerging science into action by providing input into the APSS through sharing experience & knowledge.
Reducing Unnecessary C-Sections
One of the life-altering procedures of modern obstetrics is the performance of an appropriately timed and executed cesarean delivery and yet over performance can lead to short and long-term complications and maternal deaths. In parts of the world increased cesarean section rates are associated with rising maternal mortality rates. Therefore, the avoidance of performing unnecessary cesarean births has become an important long-term strategy in reducing maternal mortality.
Sepsis is a growing issue worldwide. This session will review and discuss the latest APSS #9A: Early Detection & Treatment of Sepsis for High-income Countries and the new APSS #9B: Early Detection & Treatment of Sepsis for Low and Middle-income Countries. Participants will share ideas and make suggestions to improve the APSS based on their knowledge and experience. The goal of the working group session is to facilitate revisions that increase APSS effectiveness and identify ways to disseminate APSSs more widely.
Should drug shortages be viewed as a patient safety issue? That is one of the issues the working group will tackle in this session. Pharmaceutical shortages have a profound effect on clinical practice and patient outcomes and increase health care costs. The objectives of the session are to understand the reasons for drug shortages and define alternatives for shortage prevention and mitigation. Participants will also discuss the role of technology in coming up with solutions.
For more information on the breakout sessions, or to register, please visit http://www.cvent.com/events/6th-annual-world-patient-safety-science-technology-summit/event-summary-354a3027b4904b42940fda0fc321463f.aspx.
About Patient Safety Movement Foundation:
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.
Patient Safety Movement Foundation
Tanya Lyon, (949) 351-2858
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i